Titan Pharmaceuticals
15
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
60.0%
9 terminated/withdrawn out of 15 trials
40.0%
-46.5% vs industry average
47%
7 trials in Phase 3/4
33%
2 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
STEPS Trial - Spheramine Safety and Efficacy Study
Role: collaborator
Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
Role: lead
Pilot Study of Safety and Efficacy of Spheramine
Role: collaborator
A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
Role: lead
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
Role: lead
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
Role: lead
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Role: lead
Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Role: lead
Re-Treatment Study of Probuphine in Opioid Addiction
Role: lead
Study of Probuphine in Patients With Opioid Dependence
Role: lead
Study of DITPA in Patients With Congestive Heart Failure
Role: lead
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
Role: lead
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia
Role: lead
A Pilot Study of Pivanex in Patients With Malignant Melanoma
Role: lead
Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Role: lead
All 15 trials loaded